Skip to main content
HR 4376 117th Congress House

USTRx Act

Official title: To identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based poli… Show full official titleShow less

Official title: To identify and take action against international trade practices of high income countries that unfairly exploit innovation by deviating from market-based policies and unfairly exploit United States innovation, and for other purposes.

Introduced: July 9, 2021 Introduced by: Arrington, Jodey C. Republican · Texas See on congress.gov
Foreign Trade and International Finance
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 9, 2021
Referred to the Subcommittee on Trade.
Jul 9, 2021
Referred to the House Committee on Ways and Means.
Jul 9, 2021
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action July 9, 2021

Referred to the Subcommittee on Trade.

 Plain-English summary Congressional Research Service

Use Sovereignty To reduce Rx Act or the USTRx Act

This bill establishes the role of Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative (USTR) to conduct trade negotiations, enforce trade agreements relating to U.S. pharmaceutical products, and address acts, policies, or practices of high-income countries that adversely impact the market access of U.S. pharmaceutical manufacturers.

The USTR must annually compile a list of high-income countries based on official statistics of the International Bank for Reconstruction and Development of the World Bank. Based on that list, the negotiator must submit a report describing (1) such countries' actions and impacts relating to the pharmaceutical trade, and (2) the current status of any responsive actions taken by the United States.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4376: USTRx Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-4376/
MLA
"H.R. 4376: USTRx Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-4376/.
Bluebook (legal)
H.R. 4376, 117th Cong. (2026), https://openamerica.io/bill/117-HR-4376/.
Markdown link
[H.R. 4376: USTRx Act](https://openamerica.io/bill/117-HR-4376/)
Report a problem